NVO

64.85

4.00% -2.70

Dopo l'orario di chiusura: 65.00 0.15 +0.23%

Novo Nordisk Adr (NVO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché NVO Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$67.55

Aprire:

$65.91

Volume 24 ore:

12.02M

Relative Volume:

1.33

Capitalizzazione di mercato:

$291.20B

Reddito:

$42.09B

Utile/perdita netta:

$14.65B

Rapporto P/E:

19.75

EPS:

3.2833

Flusso di cassa netto:

$10.11B

1 W Prestazione:

-1.14%

1M Prestazione:

+5.28%

6M Prestazione:

-39.51%

1 anno Prestazione:

-48.81%

Intervallo 1D:

$64.40

$65.96

Intervallo di 1 settimana:

$64.40

$69.86

Portata 52W:

$57.00

$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Nome

Novo Nordisk Adr

Settore

Healthcare (1153)

Industria

Drug Manufacturers - General (19)

Telefono

Indirizzo

Dipendente

76,302

Cinguettio

@novonordisk

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

NVO's Discussions on Twitter

Confronta NVO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVO Novo Nordisk Adr	64.85	291.20B	42.09B	14.65B	10.11B	3.2833
LLY Lilly Eli Co	751.45	681.85B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	155.66	370.90B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	185.58	342.01B	57.37B	4.20B	17.83B	2.35
NVS Novartis Ag Adr	110.13	219.89B	53.22B	12.86B	14.85B	6.39

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2025-03-13	Aggiornamento	Kepler	Hold → Buy
2025-03-03	Downgrade	Stifel	Buy → Hold
2025-02-12	Iniziato	Morgan Stanley	Equal-Weight
2025-01-06	Aggiornamento	Bernstein	Underperform → Mkt Perform
2024-05-30	Iniziato	Goldman	Buy
2024-04-12	Iniziato	BMO Capital Markets	Outperform
2024-01-23	Iniziato	Morgan Stanley	Overweight
2024-01-16	Ripresa	UBS	Neutral
2023-12-01	Iniziato	Cantor Fitzgerald	Overweight
2023-10-02	Iniziato	Argus	Buy
2023-07-14	Iniziato	HSBC Securities	Buy
2022-07-15	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-06-28	Downgrade	UBS	Neutral → Sell
2022-06-27	Aggiornamento	Exane BNP Paribas	Underperform → Neutral
2022-06-07	Aggiornamento	JP Morgan	Neutral → Overweight
2022-05-31	Aggiornamento	Guggenheim	Neutral → Buy
2022-04-25	Aggiornamento	Cowen	Market Perform → Outperform
2022-04-12	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-03-16	Aggiornamento	Deutsche Bank	Hold → Buy
2022-01-25	Downgrade	Liberum	Hold → Sell
2021-12-20	Downgrade	JP Morgan	Overweight → Neutral
2021-12-17	Downgrade	Deutsche Bank	Buy → Hold
2021-01-20	Downgrade	Credit Suisse	Outperform → Neutral
2021-01-15	Iniziato	Deutsche Bank	Buy
2020-09-29	Iniziato	Berenberg	Hold
2020-07-06	Downgrade	BofA Securities	Buy → Neutral
2020-05-11	Downgrade	UBS	Buy → Neutral
2020-05-04	Iniziato	Cowen	Market Perform
2020-03-16	Aggiornamento	BofA/Merrill	Neutral → Buy
2020-01-03	Downgrade	Guggenheim	Buy → Neutral
2019-11-18	Aggiornamento	Barclays	Equal Weight → Overweight
2019-09-17	Aggiornamento	Citigroup	Neutral → Buy
2019-08-30	Downgrade	Jefferies	Hold → Underperform
2019-06-20	Downgrade	Deutsche Bank	Buy → Hold
2019-06-11	Aggiornamento	Barclays	Underweight → Equal Weight
2019-04-29	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-01-29	Iniziato	Exane BNP Paribas	Outperform
2018-12-11	Ripresa	Jefferies	Hold
2018-10-09	Iniziato	Guggenheim	Buy
2017-12-29	Aggiornamento	JP Morgan	Underweight → Neutral
2017-12-06	Aggiornamento	BofA/Merrill	Neutral → Buy
2017-12-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2017-09-25	Downgrade	Exane BNP Paribas	Outperform → Neutral
2017-09-06	Aggiornamento	BofA/Merrill	Underperform → Neutral

Mostra tutto

Novo Nordisk Adr Borsa (NVO) Ultime notizie

May 08, 2025

Post-Earnings Dip: Why This Beaten-Down Stock Is a No-Brainer Buy - The Motley Fool

May 08, 2025

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - TradingView

May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

Novo Nordisk cuts guidance but says generic competition will ease - Sharecast.com

May 07, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Canada

May 07, 2025

May 06, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

Apr 29, 2025